Eli Lilly and Company has released updated Phase 3 EMBER-3 results for Inluriyo, also known as imlunestrant, its oral estrogen receptor antagonist, in patients with estrogen receptor-positive and human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. These new data, presented at the 2025 San Antonio Breast Cancer Symposium and published in Annals
Lilly’s Jaypirca reduced progression risk by 80% in frontline CLL. Explore what this changes for therapy sequencing, safety, and BTK inhibitor strategy.
Eli Lilly’s $6B Alabama facility will manufacture orforglipron and peptide APIs. Explore how this reshoring move could transform U.S. drug manufacturing.
Lilly’s Jaypirca met its Phase 3 target in CLL, matching Imbruvica on response rate and showing superior safety. Could this rewire frontline BTK therapy?
Eli Lilly and Indiana University are launching a $40M clinical trial and Alzheimer’s research initiative in Indiana. See what it could mean for U.S. pharma.